Dessa data ska bedömas i relation till läkemedlets totala säkerhetsprofil, i synnerhet den viktiga hema - tologiska toxiciteten (se avsnitt 4. 8). ###>These data should be evaluated in the context of the overall safety profile of the medicinal product, in particular to the important haematological toxicity (see section 4.8).